Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises AstraZeneca on the sale of a pharmaceutical portfolio
Mandate

Vinge advises AstraZeneca on the sale of a pharmaceutical portfolio

June 04, 2007

Vinge is advising AstraZeneca on the sale of a large number of pharmaceuticals to Recip AB. The sale includes a portfolio of infection drugs for sale in Sweden, Norway, Denmark and Iceland. The annual sales of the 17 drugs included in the portfolio are SEK 240 million.

AstraZeneca is represented by partner Malin Leffler, assisted by Anna Berntsson and Claes Henriksson.

Related

Vinge advises Revivo Group on the acquisition of Solidenergy

 Revivo Group, a portfolio company of Helix Kapital, has acquired Solidenergy, a leading provider of surface treatment services in the Norwegian market. The company operates within the energy, offshore and infrastructure sectors and is headquartered in Ågotnes outside Bergen. Solidenergy employs approximately 600 people.
March 03, 2026

Vinge advises on the sale of Poseidon Diving Group

 Vinge has advised the sellers in connection with the sale of Poseidon Diving Group AB to Argo Defence Group AB. Poseidon was founded in 1958 and is a leading manufacturer of advanced diving and breathing equipment.
March 02, 2026

Vinge has advised management of atNorth in connection with the sale of atNorth to CPP Investments and Equinix

 Vinge has advised management of atNorth on the sale of atNorth to Canada Pension Plan Investment Board (CPP Investments) and Equinix (EMEA) Management, Inc. from Partners Group and the minority shareholders.
March 02, 2026